Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2026-01-26 00:00:00 ET · period of report 2026-01-23 · accession 0001653881-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-26 | 2026-01-23 | RCUS | Goeltz II Robert C. | CFO | A - Grant | $0.00 | +24.0K | 91.9K | +35% | $0 |
| D | 2026-01-26 | 2026-01-23 | RCUS | Goeltz II Robert C. | CFO | A - Grant | $0.00 | +96.0K | 96.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-23 | A | A | 24,000 | $0.00 | 91,924 | D | — | — | (F1) Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. (F2) Includes the unvested portion of the Reporting Person's RSU grants. |
| 2 | Derivative | Stock Option (right to buy) | 2026-01-23 | A | A | 96,000 | $0.00 | 96,000 | D | $22.13 · — to 2036-01-22 | 96,000 Common Stock | (F3) The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |